>
Switch to:

Biohaven Pharmaceutical Holding Co Piotroski F-Score

: 3 (As of Today)
View and export this data going back to 2017. Start your Free Trial

Warning Sign:

Piotroski F-Score of 3 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biohaven Pharmaceutical Holding Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

The historical rank and industry rank for Biohaven Pharmaceutical Holding Co's Piotroski F-Score or its related term are showing as below:

NYSE:BHVN' s Piotroski F-Score Range Over the Past 10 Years
Min: 2   Med: 4   Max: 5
Current: 3

2
5

During the past 6 years, the highest Piotroski F-Score of Biohaven Pharmaceutical Holding Co was 5. The lowest was 2. And the median was 4.


Biohaven Pharmaceutical Holding Co Piotroski F-Score Historical Data

The historical data trend for Biohaven Pharmaceutical Holding Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biohaven Pharmaceutical Holding Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Piotroski F-Score
Premium Member Only N/A 4.00 3.00 2.00 3.00

Biohaven Pharmaceutical Holding Co Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Piotroski F-Score Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 4.00 3.00 4.00 3.00

Competitive Comparison

For the Biotechnology subindustry, Biohaven Pharmaceutical Holding Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Biohaven Pharmaceutical Holding Co Piotroski F-Score Distribution

For the Biotechnology industry and Healthcare sector, Biohaven Pharmaceutical Holding Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Biohaven Pharmaceutical Holding Co's Piotroski F-Score falls into.


How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun21) TTM:Last Year (Jun20) TTM:
Net Income was -195.189 + -217.736 + -264.968 + -210.619 = $-888.5 Mil.
Cash Flow from Operations was -164.106 + -212.238 + -205.674 + -227.042 = $-809.1 Mil.
Revenue was 17.664 + 35.114 + 43.823 + 92.933 = $189.5 Mil.
Gross Profit was 13.42 + 25.146 + 30.961 + 75.594 = $145.1 Mil.
Average Total Assets from the begining of this year (Jun20)
to the end of this year (Jun21) was
(424.255 + 782.015 + 686.975 + 1003.159 + 845.893) / 5 = $748.4594 Mil.
Total Assets at the begining of this year (Jun20) was $424.3 Mil.
Long-Term Debt & Capital Lease Obligation was $274.1 Mil.
Total Current Assets was $666.6 Mil.
Total Current Liabilities was $399.1 Mil.
Net Income was -106.167 + -149.264 + -172.937 + -180.934 = $-609.3 Mil.

Revenue was 0 + 0 + 1.151 + 9.698 = $10.8 Mil.
Gross Profit was 0 + 0 + 0.727 + 6.64 = $7.4 Mil.
Average Total Assets from the begining of last year (Jun19)
to the end of last year (Jun20) was
(490.908 + 439.087 + 344.264 + 532.669 + 424.255) / 5 = $446.2366 Mil.
Total Assets at the begining of last year (Jun19) was $490.9 Mil.
Long-Term Debt & Capital Lease Obligation was $0.0 Mil.
Total Current Assets was $362.6 Mil.
Total Current Liabilities was $166.4 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biohaven Pharmaceutical Holding Co's current Net Income (TTM) was -888.5. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Biohaven Pharmaceutical Holding Co's current Cash Flow from Operations (TTM) was -809.1. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Jun20)
=-888.512/424.255
=-2.09428763

ROA (Last Year)=Net Income/Total Assets (Jun19)
=-609.302/490.908
=-1.2411735

Biohaven Pharmaceutical Holding Co's return on assets of this year was -2.09428763. Biohaven Pharmaceutical Holding Co's return on assets of last year was -1.2411735. ==> Last year is higher ==> Score 0.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Biohaven Pharmaceutical Holding Co's current Net Income (TTM) was -888.5. Biohaven Pharmaceutical Holding Co's current Cash Flow from Operations (TTM) was -809.1. ==> -809.1 > -888.5 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Jun21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun20 to Jun21
=274.138/748.4594
=0.3662697

Gearing (Last Year: Jun20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Jun19 to Jun20
=0/446.2366
=0

Biohaven Pharmaceutical Holding Co's gearing of this year was 0.3662697. Biohaven Pharmaceutical Holding Co's gearing of last year was 0. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Jun21)=Total Current Assets/Total Current Liabilities
=666.58/399.132
=1.67007406

Current Ratio (Last Year: Jun20)=Total Current Assets/Total Current Liabilities
=362.562/166.417
=2.1786356

Biohaven Pharmaceutical Holding Co's current ratio of this year was 1.67007406. Biohaven Pharmaceutical Holding Co's current ratio of last year was 2.1786356. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Biohaven Pharmaceutical Holding Co's number of shares in issue this year was 65.112. Biohaven Pharmaceutical Holding Co's number of shares in issue last year was 58.742. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=145.121/189.534
=0.76567265

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=7.367/10.849
=0.67904876

Biohaven Pharmaceutical Holding Co's gross margin of this year was 0.76567265. Biohaven Pharmaceutical Holding Co's gross margin of last year was 0.67904876. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Jun20)
=189.534/424.255
=0.44674547

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Jun19)
=10.849/490.908
=0.02209986

Biohaven Pharmaceutical Holding Co's asset turnover of this year was 0.44674547. Biohaven Pharmaceutical Holding Co's asset turnover of last year was 0.02209986. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+0+1+0+0+0+1+1
=3

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Biohaven Pharmaceutical Holding Co has an F-score of 3. It is a bad or low score, which usually implies poor business operation.

Biohaven Pharmaceutical Holding Co  (NYSE:BHVN) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Biohaven Pharmaceutical Holding Co Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Biohaven Pharmaceutical Holding Co's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Biohaven Pharmaceutical Holding Co Business Description

Biohaven Pharmaceutical Holding Co logo
Industry
Healthcare » Biotechnology NAICS : 325412 SIC : 2834
Traded in Other Exchanges
Address
C/o Biohaven Pharmaceuticals, Inc., 215 Church Street, New Haven, CT, USA, 06510
Biohaven Pharmaceutical Holding Co Ltd is a clinical-stage biopharmaceutical company. It has a portfolio of late-stage product candidates targeting neurological diseases, including rare disorders. The company product candidates are based on multiple mechanisms-calcitonin gene-related peptide receptor antagonists, glutamate modulators and myeloperoxidase inhibitor. Its pipeline products include BHV-3100, BHV5000, BHV5500, among others.
Executives
Bailey Gregory director 4 A CHESHAM STREET LONDON X0 SW1X8DT
Gentile Kimberly officer: SVP, Clinical Operations C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Childs John W director 111 HUNTINGTON AVENUE SUITE 2900 BOSTON MA 02199
Berman Robert officer: Special Projects & Med Ovrsght C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Doogan Declan director C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Stock Elyse officer: Chief Medical Officer 215 CHURCH STREET NEW HAVEN CT 06510
Engelhart James officer: Chief Financial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Tilton John officer: Chief Commercial Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Hugin Robert J director C/O THE MEDICINES CO 8 CAMPUS DR PARSIPPANY NJ 07054
Heffernan Michael Thomas director C/O CORNERSTONE THERAPEUTICS INC. 1255 CRESCENT GREEN DRIVE, SUITE 250 CARY NC 27518
Gregory Julia P director 8800 TECHNOLOGY FOREST PLACE THE WOODLANDS TX 77381
Aguiar Eric director 888 7TH AVENUE 12TH FLOOR NEW YORK NY 10106
Coric Vlad director, officer: Chief Executive Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510
Jones William A Jr officer: CCO-Migraine & Common Disease NITROMED, INC. 125 SPRING STREET LEXINGTON MA 02421
Conway Charles officer: Chief Scientific Officer C/O BIOHAVEN PHARMACEUTICAL HOLDING COMP 234 CHURCH STREET NEW HAVEN CT 06510

Biohaven Pharmaceutical Holding Co Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)